| Literature DB >> 24423782 |
Susan Samuel1, Martin Bitzan2, Michael Zappitelli2, Allison Dart3, Cherry Mammen4, Maury Pinsk5, Andrey V Cybulsky6, Michael Walsh7, Greg Knoll8, Michelle Hladunewich9, Joanne Bargman9, Heather Reich9, Atul Humar10, Norman Muirhead11.
Abstract
The KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for management of glomerulonephritis was recently released. The Canadian Society of Nephrology convened a working group to review the recommendations and comment on their relevancy and applicability to the Canadian context. A subgroup of pediatric nephrologists reviewed the guideline statements for management of childhood nephrotic syndrome and agreed with most of the guideline statements developed by KDIGO. This commentary highlights areas in which there is lack of evidence and areas in need of translation of evidence into clinical practice. Areas of controversy or uncertainty, including the length of corticosteroid therapy for the initial presentation and relapses, definitions of steroid resistance, and choice of second-line agents, are discussed in more detail. Existing practice variation is also addressed.Entities:
Keywords: Canadian Society of Nephrology (CSN); Clinical practice guideline implementation; KDIGO (Kidney Disease: Improving Global Outcomes); corticosteroids; glomerulonephritis; nephrotic syndrome; pediatric
Mesh:
Substances:
Year: 2014 PMID: 24423782 DOI: 10.1053/j.ajkd.2013.12.002
Source DB: PubMed Journal: Am J Kidney Dis ISSN: 0272-6386 Impact factor: 8.860